© Copyright 2025 American Medical Association. All rights reserved.
The CPT® Code 90291 refers to human cytomegalovirus immune globulin (CMV-IgIV), which is specifically formulated for intravenous use. This immunizing agent is a concentrated solution containing antibodies that provide effective, short-term passive immunity to individuals exposed to cytomegalovirus (CMV). Unlike active immunization, where the recipient's immune system is stimulated to produce its own antibodies, CMV-IgIV offers passive protection by supplying pre-formed antibodies directly into the bloodstream. These antibodies are derived from the pooled blood of multiple donors who have previously developed immunity to CMV, ensuring a robust source of protective agents. The administration of this immune globulin is crucial for individuals at high risk of CMV infection, as it helps to mitigate the potential effects of the virus without requiring the recipient's immune system to engage in antibody production. This code is specifically used to report the use of CMV-IgIV and does not encompass any additional services or procedures associated with its administration.
© Copyright 2025 Coding Ahead. All rights reserved.
The administration of human cytomegalovirus immune globulin (CMV-IgIV) is indicated for specific clinical scenarios where protection against cytomegalovirus is necessary. The following conditions warrant the use of this immunizing agent:
The procedure for administering human cytomegalovirus immune globulin (CMV-IgIV) involves several critical steps to ensure safety and efficacy. The following procedural steps outline the process:
Following the administration of CMV-IgIV, patients may require specific post-procedure care to ensure their safety and well-being. It is important to monitor the patient for any delayed reactions or side effects that may occur after the infusion. Patients should be advised to report any unusual symptoms, such as fever, rash, or difficulty breathing, to their healthcare provider. Additionally, follow-up appointments may be scheduled to assess the effectiveness of the treatment and to monitor the patient’s overall health status. Documentation of the administration, including the lot number of the immune globulin and any reactions observed, is essential for compliance and future reference.
Short Descr | CMV IG IV | Medium Descr | CYTOMEGALOVIRUS IMMUNE GLOBULIN HUMAN IV | Long Descr | Cytomegalovirus immune globulin (CMV-IgIV), human, for intravenous use | Status Code | Not Valid for Medicare Purposes | Global Days | XXX - Global Concept Does Not Apply | PC/TC Indicator (26, TC) | 9 - Not Applicable | Multiple Procedures (51) | 9 - Concept does not apply. | Bilateral Surgery (50) | 9 - Concept does not apply. | Physician Supervisions | 09 - Concept does not apply. | Assistant Surgeon (80, 82) | 9 - Concept does not apply. | Co-Surgeons (62) | 9 - Concept does not apply. | Team Surgery (66) | 9 - Concept does not apply. | Diagnostic Imaging Family | 99 - Concept Does Not Apply | APC Status Indicator | Non-Covered Service, not paid under OPPS | Type of Service (TOS) | 1 - Medical Care | Berenson-Eggers TOS (BETOS) | P6D - Minor procedures - other (non-Medicare fee schedule) | MUE | 0 | CCS Clinical Classification | 228 - Prophylactic vaccinations and inoculations |
Date
|
Action
|
Notes
|
---|---|---|
2011-01-01 | Changed | Short description changed. |
1999-01-01 | Added | First appearance in code book in 1999. |